Welcome to the Wet AMD & DME Drug Development Summit  - Now Live

Welcome to the Wet AMD & DME Drug Development Summit

Running virtually for 2021, the inaugural Wet AMD & DME Drug Development Summit comes at a critical juncture, as the research community progresses novel drug candidates targeting angiogenesis-driven disease and a pandemic further exposes the current treatment limitations for a global aging population.

Join this dedicated industry forum, to network online and learn from senior leaders of discovery, translational sciences, and clinical development from the likes of Boehringer Ingelheim, Doheny Eye Institute, Aerpion Therapeutics, Genentech, Ocugen and more to address the specific challenges for the biopharmaceutical and biotechnology in its efforts to bring long-lasting treatments which reduce clinical burden and can be commercialized to become the new standard-of-care in this vast ophthalmology indication.

Navigate across 3 jam-packed days including interactive workshops exploring clinical biomarkers for testing drugs in patients and developing preclinical models to predict human disease and efficacy of a drug.

Companies Registered to Attend Include:

abbvie
Aerie-Pharmaceuticals-Logo
Alkahest-logo
Allgenesis Bio
boehringer
Catalyst
Gemini Therapeutics
Genentech-Logo.wine
Graybug
gyroscope-vision-for-life-logo-dark-new
iconic
daichii
kala-logo-footer
meduniwienlogo_2-1746
novartis
ocular
Yale-University-Logo-Header-VNIOiena8OGMXs8hu65vBXbujKPXBcgD
radboud-university
regeneron
IU_V_P1_S1
Roche_Logo.svg
Santen_Pharmaceutical_company_logo.svg
Spark_Therapeutics_Label
surrozen-logo-final-large-1
polyactiva
wake forest

Expert Speakers Include:

Feedback from the Dry AMD Therapeutic Development Summit:

“Thorough update on the scientific, regulatory and commercial status of dry AMD”

CEO, Drusolv Therapeutics

“Informative and enlightening”

Chief Medical Officer, Eyevensys